BIOC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Stats
Current Price	$2.02
Today's Volume	59 476.00
Average Volume	145 576
Market Cap	2.97M
EPS	$-63.61
P/E	-0.0300
ATR14	$0.0190 (0.95%)

Volume Correlation

Long: 0.24 (neutral)

Short: 0.80 (moderate)

Signal:(47.39) Neutral

Biocept Inc Correlation

10 Most Positive Correlations
ALHC	0.952
TUEM	0.95
BFRI	0.948
MDRX	0.947
NRXP	0.946
FIBK	0.946
SVAC	0.942
EBC	0.941
CPTN	0.94
SPFI	0.937

10 Most Negative Correlations
AMRB	-0.973
QNST	-0.94
MCFT	-0.938
OBT	-0.938
PTOC	-0.938
APXI	-0.933
SGEN	-0.933
LSTR	-0.933
RMBS	-0.93
GPACU	-0.929

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biocept Inc Correlation - Currency/Commodity

-0.06
( neutral )

0.12
( neutral )

0.00
( neutral )

0.67
( moderate )

Biocept Inc Financials

Annual 2021
Revenue: $61.25M
Gross Profit: $23.49M (38.34%)
EPS: $-0.190

Q1 2023
Revenue: $673 000
Gross Profit: $-2.36M (-349.93%)
EPS: $-0.410

Q3 2022
Revenue: $5.59M
Gross Profit: $-189 000 (-3.38%)
EPS: $-0.330

Q2 2022
Revenue: $10.61M
Gross Profit: $2.59M (24.39%)
EPS: $-0.320

Biocept Inc

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.